|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.00 GBX | +1.39% |
|
+8.15% | +25.86% |
| 24/02 | Avacta hails new data supporting proprietary preCision platform | AN |
| 24/02 | Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis | MT |
Company Valuation: Avacta Group Plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 284.3 | 316.8 | 298.4 | 326 | 182.9 | 314.9 | 314.9 | - |
| Change | - | 11.41% | -5.82% | 9.26% | -43.88% | 72.14% | 0% | - |
| Enterprise Value (EV) 1 | 238.5 | 290.6 | 275.3 | 309.4 | 170.1 | 309.5 | 331.7 | 368.4 |
| Change | - | 21.86% | -5.26% | 12.37% | -45.02% | 81.98% | 7.18% | 11.04% |
| P/E ratio | - | - | -7.49x | -12.7x | -3.26x | -10.5x | -12.2x | -9.15x |
| PBR | - | - | - | 14.6x | - | -26.3x | -9.49x | - |
| PEG | - | - | - | 0.3x | -0x | 0.2x | 0.9x | -0.3x |
| Capitalization / Revenue | 78.2x | 108x | 30.9x | 14x | 7.49x | 50.4x | - | - |
| EV / Revenue | 65.6x | 98.8x | 28.5x | 13.3x | 6.96x | 49.5x | - | - |
| EV / EBITDA | -16.7x | -10.9x | -11.6x | -15.4x | -6.49x | -12.9x | -13.8x | -9.87x |
| EV / EBIT | -14.5x | -9.99x | -10.3x | -11.2x | -5.22x | -11x | -12.1x | -8.94x |
| EV / FCF | -19.7x | -13.3x | 17.4x | -19.2x | -7.11x | -8.77x | -9.62x | -6.03x |
| FCF Yield | -5.07% | -7.51% | 5.75% | -5.2% | -14.1% | -11.4% | -10.4% | -16.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | -0.1535 | -0.0915 | -0.1534 | -0.0687 | -0.0588 | -0.0787 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3.636 | 2.941 | 9.653 | 23.25 | 24.42 | 6.25 | - | - |
| EBITDA 1 | -14.29 | -26.71 | -23.67 | -20.14 | -26.2 | -24.07 | -24.08 | -37.3 |
| EBIT 1 | -16.44 | -29.08 | -26.68 | -27.56 | -32.56 | -28.22 | -27.52 | -41.22 |
| Net income 1 | -18.89 | - | -39.19 | -24.95 | -52.84 | -35.12 | -31.55 | -28.6 |
| Net Debt 1 | -45.87 | -26.19 | -23.05 | -16.63 | -12.87 | -5.432 | 16.8 | 53.44 |
| Reference price 2 | 1.1400 | 1.2640 | 1.1500 | 1.1650 | 0.5000 | 0.7200 | 0.7200 | 0.7200 |
| Nbr of stocks (in thousands) | 2,49,420 | 2,50,617 | 2,59,438 | 2,79,822 | 3,65,897 | 4,37,405 | 4,37,405 | - |
| Announcement Date | 22/04/21 | 06/04/22 | 25/04/23 | 30/04/24 | 06/06/25 | - | - | - |
1GBP in Million2GBP
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.48x | 49.52x | -12.86x | -.--% | 42Cr | |
| 41.62x | 9.71x | 35.05x | 0.03% | 4.35TCr | |
| 15.77x | 5.61x | 12.36x | 1.9% | 3.99TCr | |
| -51.88x | 17.46x | -57.7x | -.--% | 3.01TCr | |
| -17.43x | 4.11x | -7.72x | -.--% | 2.16TCr | |
| 26.89x | 5.54x | 15.37x | -.--% | 1.86TCr | |
| 21.84x | 4.15x | 13.57x | -.--% | 1.65TCr | |
| -318.22x | 26.4x | 1453.35x | -.--% | 1.31TCr | |
| -13.71x | 6123.95x | -17.5x | -.--% | 1.2TCr | |
| -162.05x | 39.38x | -156.41x | -.--% | 1.16TCr | |
| Average | -46.76x | 628.58x | 127.75x | 0.19% | 2.07TCr | |
| Weighted average by Cap. | -23.38x | 365.31x | 84.99x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- AVCT Stock
- Valuation Avacta Group Plc
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition